A third coronavirus vaccine may be made available in India soon. Serum Institute of India (SII) CEO Adar Poonawala has given important information about this.
Poonawalla said in a tweet that, the Serum Institute has also demonstrated excellent efficacy results in partnership with Novavax for the COVID-19 vaccine. He further added that he has applied to start testing this vaccine in India and is expected to launch the vaccine – Covovax by June 2021.
According to Novovax, the Covid-19 vaccine ‘Novovax’ has shown 89.3% efficacy in its Phase 3 clinical trial in the United Kingdom.
A study assessed the efficacy of this vaccine with high transmission, especially in the United Kingdom, with new types of emerging and widely transmitted viruses with great speed.
The study was conducted in partnership with the UK Government Vaccine Taskforce.
Novavax had also previously announced the successful results of its Phase 2B study, which was conducted in South Africa.
